Tert-butyl (S)-((1,2,3,4-tetrahydroisoquinolin-3-yl)methyl)carbamate, 96%, 100mg

2-(Pyridin-3-yl)acetamide, 95.0%, 10g

2-Bromo-4-iodoanisole, 98.0%, 10g

3-[[(1,1-Dimethylethyl)diphenylsilyl]oxy]-1-propanamine, 1g

3-Bromo-6-chloro-2-(difluoromethyl)pyridine, 98%, 1g

4-Oxocyclohexanecarboxylic acid, 97.0%, 500g

Plan phase PLPHi 20x/0.40 infinity corrected IOS objective. Working distance 8.80 mm

Potassium {1-[(tert-butoxy)carbonyl]pyrrolidin-3-yl}trifluoroboranuide, 98+%, 1g

2-ethynyl-2,6,6-trimethyltetrahydro-2H-pyran, 95.0%, 1g

4-Chloro-1(2H)-isoquinolone, 95.0%, 5g

2,5-Dimethoxycinnamic Acid>97.0%(T)10g

Methyl 4-bromo-3,5-dihydroxybenzoate, 95.0%, 1g

4-Methylquinolin-2-ol, 95.0%, 500g